Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | QPCT | Q16769 | 9/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15152621 | 0.87 | IDH1 (0.35) | PIK3CAMTORIDH1QPCTHDAC1 | |
| SCHEMBL8251549 | 0.86 | MAPT (0.39) | PIK3CAMTORIDH1QPCT | |
| SCHEMBL13862087 | 0.85 | PIK3CA (0.39) | PIK3CAMTORIDH1QPCTHDAC1 | |
| SCHEMBL8251051 | 0.84 | IDH1 (0.38) | PIK3CAMTORIDH1QPCTHDAC1 | |
| SCHEMBL2107339 | 0.84 | IDH1 (0.38) | PIK3CAMTORIDH1QPCTHDAC1 | |
| SCHEMBL8257483 | 0.79 | F10 (0.41) | PIK3CAQPCT | |
| SCHEMBL18770297 | 0.78 | IDH1 (0.33) | PIK3CAMTORIDH1QPCTHDAC1 | |
| SCHEMBL2365813 | 0.77 | CPS1 (0.41) | PIK3CAIDH1 | |
| SCHEMBL2365822 | 0.77 | CPS1 (0.41) | PIK3CAIDH1 | |
| SCHEMBL2366957 | 0.74 | CPS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1745047-B1 | PYRAZOLO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE ADENOSINE-A2A- RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1622912-B1 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | PIK3CA 1023/4885MTOR 1952/4885IDH1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.